Scrip
Clinica
Scrip Regulatory Affairs
Scrip Clinical Research
AnimalPharm
Email ID
Password
Forgotten your password?
Sign me in automatically next time
Advanced Search
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Deals
|
M&A
|
Financials
|
Strategy
|
Lifecycle Management
|
Legal
|
Lilly is clear about the challenges for 2011, as pressures on patent cliff mount
28 January 2011
Nancy Faigen
nancy.faigen@informausa.com
Please Login to read the full article.
Not a subscriber?
Subscribe to Scrip
Request a FREE Trial
RELATED CONTENT
NEWS
Scrip News
End of an era in antibiotic blockbusters as FDA approves Levaquin generics
Sanofi impresses with new growth and efficiency targets
Gilenya and Tasigna drive new product growth at Novartis
Positive Phase III data for LifeCycle's 'improved Prograf' despite higher drop-out
Other Informa News
Quarterly results round-up: St Jude and Quest cut jobs to rein in costs, Baxter strong again
Quarterly results round-up: Boston still on road to recovery, Thermo Fisher and Zimmer solid
COMMENT
Scrip Comment
Blade of truth lacerates the a web of intrigue
FEATURES
Other Informa Features
Out of joint: Japan must nurture markets for innovative technologies
About Us
Getting Started
Subscribe
Free Trial
Advertise
Awards
White Papers
Executive Briefing
Classifieds
Recruitment
JOB OF THE WEEK
Promote your vacancy here
SCRIP's ONLINE DIRECTORY
Classified ads